|
1
|
Kwan JM, Fialho AM, Kundu M, Thomas J,
Hong CS, Das Gupta TK and Chakrabarty AM: Bacterial proteins as
potential drugs in the treatment of leukemia. Leuk Res.
33:1392–1399. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bhojwani D, Yang JJ and Pui CH: Biology of
childhood acute lymphoblastic leukemia. Pediatr Clin North Am.
62:47–60. 2015. View Article : Google Scholar
|
|
3
|
Randhawa JK and Ferrajoli A: A review of
supportive care and recommended preventive approaches for patients
with chronic lymphocytic leukemia. Expert Rev Hematol. 9:235–244.
2016. View Article : Google Scholar
|
|
4
|
Morabito F, Gentile M, Seymour JF and
Polliack A: Ibrutinib, idelalisib and obinutuzumab for the
treatment of patients with chronic lymphocytic leukemia: Three new
arrows aiming at the target. Leuk Lymphoma. 56:3250–3256. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fabbri G and Dalla-Favera R: The molecular
pathogenesis of chronic lymphocytic leukaemia. Nat Rev Cancer.
16:145–162. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nimmanapalli R and Bhalla K: Novel
targeted therapies for Bcr-Abl positive acute leukemias: Beyond
STI571. Oncogene. 21:8584–8590. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Soni G and Yadav KS: Applications of
nanoparticles in treatment and diagnosis of leukemia. Mater Sci Eng
C. 47:156–164. 2015. View Article : Google Scholar
|
|
8
|
Terme M, Borg C, Guilhot F, Masurier C,
Flament C, Wagner EF, Caillat-Zucman S, Bernheim A, Turhan AG,
Caignard A and Zitvogel L: BCR/ABL promotes dendritic cell-mediated
natural killer cell activation. Cancer Res. 65:6409–6417. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nagata Y and Todokoro K: Requirement of
activation of JNK and p38 for environmental stress-induced
erythroid differentiation and apoptosis and of inhibition of ERK
for apoptosis. Blood. 94:853–863. 1999.PubMed/NCBI
|
|
10
|
Jia L, Patwari Y, Kelsey SM and Newland
AC: Trail-induced apoptosis in Type I leukemic cells is not
enhanced by overexpression of bax. Biochem Biophys Res Commun.
283:1037–1045. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Negrini M, Ferracin M, Sabbioni S and
Croce CM: MicroRNAs in human cancer: From research to therapy. J
Cell Sci. 120:1833–1840. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Calin GA, Dumitru CD, Shimizu M, Bichi R,
Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al:
Frequent deletions and downregulation of micro-RNA genes miR15 and
miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci
USA. 99:15524–15529. 2002. View Article : Google Scholar
|
|
13
|
Klein U, Lia M, Crespo M, Siegel R, Shen
Q, Mo T, Ambesi-Impiombato A, Califano A, Migliazza A, Bhagat G and
Dalla-Favera R: The DLEU2/miR-15a/161 cluster controls B cell
proliferation and its deletion leads to chronic lymphocytic
leukemia. Cancer Cell. 17:28–40. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cimmino A, Calin GA, Fabbri M, Iorio MV,
Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, et
al: miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl
Acad Sci USA. 102:13944–13949. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Roberts AW, Davids MS, Pagel JM, Kahl BS,
Puvvada SD, Gerecitano JF, Kipps TJ, Anderson MA, Brown JR,
Gressick L, et al: Targeting BCL2 with venetoclax in relapsed
chronic lymphocytic leukemia. N Engl J Med. 374:311–322. 2016.
View Article : Google Scholar
|
|
16
|
Calin GA, Ferracin M, Cimmino A, Di Leva
G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, et
al: A microRNA signature associated with prognosis and progression
in chronic lymphocytic leukemia. N Engl J Med. 353:1793–1801. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fabbri M, Bottoni A, Shimizu M, Spizzo R,
Nicoloso MS, Rossi S, Barbarotto E, Cimmino A, Adair B, Wojcik SE,
et al: Association of a microRNA/TP53 feedback circuitry with
pathogenesis and outcome of B-cell chronic lymphocytic leukemia.
JAMA. 305:59–67. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ramasamy T, Ruttala HB, Gupta B, Poudel
BK, Choi HG, Yong CS and Kim JO: Smart chemistry-based nanosized
drug delivery systems for systemic applications: A comprehensive
review. J Control Release. 258:226–253. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Choi JY, Ramasamy T, Tran TH, Ku SK, Shin
BS, Choi HG, Yong CS and Kim JO: Systemic delivery of axitinib with
nano-hybrid liposomal nanoparticles inhibits hypoxic tumor growth.
J Mater Chem B. 3:408–416. 2015. View Article : Google Scholar
|
|
20
|
Ramasamy T, Ruttala HB, Sundaramoorthy P,
Poudel BK, Youn YS, Ku SK, Choi HG, Yong CS and Kim JO: Multimodal
selenium nanoshell-capped Au@mSiO2 nanoplatform for
NIR-responsive chemophotothermal therapy against metastatic breast
cancer. NPG Asia Mater. 10:197–216. 2018. View Article : Google Scholar
|
|
21
|
Ramasamy T, Haidar ZS, Tran TH, Choi JY,
Choi HG, Jeong JH, Shin BS, Choi HG, Yong CS and Kim JO:
Layer-by-layer assembly of liposomal nanoparticles with PEGylated
polyelectrolytes enhances systemic delivery of multiple anticancer
drugs. Acta Biomater. 10:5116–5127. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen Y, Gao DY and Huang L: In vivo
delivery of miRNAs for cancer therapy: Challenges and strategies.
Adv Drug Deliv Rev. 81:128–141. 2015. View Article : Google Scholar
|
|
23
|
Lam JK, Chow MY, Zhang Y and Leung SW:
siRNA versus miRNA as therapeutics for gene silencing. Mol Ther
Nucleic Acids. 4:e2522015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ruttala HB, Ramasamy T, Madeshwaran T,
Hiep TT, Kandasamy U, Oh KT, Choi HG, Yong CS and Kim JO: Emerging
potential of stimulus-responsive nanosized anticancer drug delivery
systems for systemic applications. Arch Pharm Res. 41:111–129.
2018. View Article : Google Scholar
|
|
25
|
Ahmadzada T, Reid G and McKenzie DR:
Fundamentals of siRNA and miRNA therapeutics and a review of
targeted nanoparticle delivery systems in breast cancer. Biophys
Rev. 10:69–86. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ganju A, Khan S, Hafeez BB, Behrman SW,
Yallapu MM, Chauhan SC and Jaggi MM: miRNA nanotherapeutics for
cancer. Drug Discov Today. 22:424–432. 2017. View Article : Google Scholar :
|
|
27
|
Yang X, Liang L, Zhang XF, Jia HL, Qin Y,
Zhu XC, Gao XM, Qiao P, Zheng Y, Sheng YY, et al: MicroRNA-26a
suppresses tumor growth and metastasis of human hepatocellular
carcinoma by targeting interleukin-6-Stat3 pathway. Hepatology.
58:158–170. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhu Y, Lu Y, Zhang Q, Liu JJ, Li TJ, Yang
JR, Zeng C and Zhuang SM: MicroRNA-26a/b and their host genes
cooperate to inhibit the G1/S transition by activating the pRb
protein. Nucleic Acids Res. 40:4615–4625. 2012. View Article : Google Scholar : PubMed/NCBI
|
